日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

PURE-seq integrates FACS and PIP-seq for single-cell genomics of ultra-rare cells.

PURE-seq 整合了 FACS 和 PIP-seq,用于超稀有细胞的单细胞基因组学研究。

Pan Sixuan, Fernández-Maestre Inés, Chang Kai-Chun, Van Haver Stéphane, Wereski Matthew G, Haugh Alexandra M, Tsai Katy K, Daud Adil I, Bowman Robert L, Vasudevan Harish N, Levine Ross L, Abate Adam R

Distinguishing between help and harm: Helper T cell subsets and immune-related adverse events

区分帮助与伤害:辅助性T细胞亚群与免疫相关不良事件

Haugh, Alexandra M; Daud, Adil I

Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors

转移性黑色素瘤至小肠:在免疫疗法和免疫检查点抑制剂时代,转移灶切除术仍然有效。

Wong, Paul; Wisneski, Andrew D; Tsai, Katy K; Chang, Tammy T; Hirose, Kenzo; Nakakura, Eric K; Daud, Adil I; Maker, Ajay V; Corvera, Carlos U

Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response

帕博利珠单抗、伊匹木单抗和阿司匹林治疗黑色素瘤的II期临床试验:临床结果和疗效转化预测因子

Quandt, Zoe; Jacob, Saya; Fadlullah, Muhammad Zaki Hidayatullah; Wu, Chaorong; Wu, Clinton; Huppert, Laura; Levine, Lauren S; Sison, Paula; Tsai, Katy K; Chow, Melissa; Kang, Jee Hye; Hwang, Jimmy; Lee, James C; Oglesby, Ariel; Venegas, Jessica; Brintz, Ben J; Tan, Aik Choon; Anderson, Mark S; Rosenblum, Michael D; Young, Arabella; Daud, Adil I

Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma

一项针对晚期实体瘤患者的泛RAF抑制剂托沃拉非尼的I期研究,随后在转移性黑色素瘤患者中开展剂量扩展研究。

Rasco, Drew W; Medina, Theresa; Corrie, Pippa; Pavlick, Anna C; Middleton, Mark R; Lorigan, Paul; Hebert, Chris; Plummer, Ruth; Larkin, James; Agarwala, Sanjiv S; Daud, Adil I; Qiu, Jiaheng; Bozon, Viviana; Kneissl, Michelle; Barry, Elly; Olszanski, Anthony J

Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy

组织特异性调节性T细胞在癌症转移中的作用:精准免疫治疗的契机

Huppert, Laura A; Green, Michael D; Kim, Luke; Chow, Christine; Leyfman, Yan; Daud, Adil I; Lee, James C

TCR-sequencing in cancer and autoimmunity: barcodes and beyond

癌症和自身免疫性疾病中的TCR测序:条形码及其他

Pauken, Kristen E; Lagattuta, Kaitlyn A; Lu, Benjamin Y; Lucca, Liliana E; Daud, Adil I; Hafler, David A; Kluger, Harriet M; Raychaudhuri, Soumya; Sharpe, Arlene H

Intratumoral therapies and in-situ vaccination for melanoma

黑色素瘤的瘤内治疗和原位疫苗接种

Huppert, Laura A; Daud, Adil I

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

帕博利珠单抗单药治疗的长期安全性及其与临床结局的关系:一项针对晚期黑色素瘤患者的里程碑式分析

Robert, Caroline; Hwu, Wen-Jen; Hamid, Omid; Ribas, Antoni; Weber, Jeffrey S; Daud, Adil I; Hodi, F Stephen; Wolchok, Jedd D; Mitchell, Tara C; Hersey, Peter; Dronca, Roxana; Joseph, Richard W; Boutros, Celine; Min, Le; Long, Georgina V; Schachter, Jacob; Puzanov, Igor; Dummer, Reinhard; Lin, Jianxin; Ibrahim, Nageatte; Diede, Scott J; Carlino, Matteo S; Joshua, Anthony M

Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial

BRAF突变型黑色素瘤患者持续性与间歇性BRAF和MEK抑制剂治疗的随机II期试验

Algazi, Alain P; Othus, Megan; Daud, Adil I; Lo, Roger S; Mehnert, Janice M; Truong, Thach-Giao; Conry, Robert; Kendra, Kari; Doolittle, Gary C; Clark, Joseph I; Messino, Michael J; Moore, Dennis F Jr; Lao, Christopher; Faller, Bryan A; Govindarajan, Rangaswamy; Harker-Murray, Amy; Dreisbach, Luke; Moon, James; Grossmann, Kenneth F; Ribas, Antoni